Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPRX Eupraxia Pharmaceuticals	$3.86 -0.5%	$3.74	$2.20 ▼ $4.48	$138.79M	0.65	13,216 shs	4,408 shs
MGNX MacroGenics	$1.52 -1.9%	$1.50	$0.99 ▼ $5.77	$95.90M	1.66	859,434 shs	952,149 shs
NKTX Nkarta	$1.86 -2.6%	$1.85	$1.31 ▼ $8.23	$131.98M	0.72	1.06 million shs	458,497 shs
VTL Vital Therapies	$0.80 -4.6%	$8.88	$0.15 ▼ $9.75	$34.10M	3.51	21.62 million shs	962,441 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPRX Eupraxia Pharmaceuticals	0.00%	-1.91%	+1.58%	-6.99%	+42.44%
MGNX MacroGenics	0.00%	-14.61%	-1.30%	-31.53%	-69.54%
NKTX Nkarta	0.00%	-2.11%	+8.14%	+12.05%	-70.57%
VTL Vital Therapies	-4.62%	+2.09%	-17.63%	-30.01%	-36.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EPRX Eupraxia Pharmaceuticals	2.2921 of 5 stars	3.7	1.0	0.0	0.0	2.7	0.0	0.6
MGNX MacroGenics	3.77 of 5 stars	3.2	1.0	0.0	4.4	2.0	2.5	0.6
NKTX Nkarta	3.6272 of 5 stars	4.6	3.0	0.0	0.0	3.0	1.7	0.6
VTL Vital Therapies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EPRX Eupraxia Pharmaceuticals	3.33	Buy	$10.50	172.02% Upside
MGNX MacroGenics	2.40	Hold	$5.71	275.94% Upside
NKTX Nkarta	3.13	Buy	$14.33	670.61% Upside
VTL Vital Therapies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VTL, EPRX, NKTX, and MGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
5/20/2025	MGNX MacroGenics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/14/2025	MGNX MacroGenics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00 ➝ $3.00
5/14/2025	MGNX MacroGenics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$6.00 ➝ $5.00
4/9/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/27/2025	NKTX Nkarta	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
3/27/2025	NKTX Nkarta	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/27/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/25/2025	MGNX MacroGenics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $2.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$0.03 per share	N/A
MGNX MacroGenics	$152.43M	0.63	N/A	N/A	$2.46 per share	0.62
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.56 per share	N/A
VTL Vital Therapies	N/A	N/A	N/A	N/A	$0.29 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EPRX Eupraxia Pharmaceuticals	-$28.22M	-$0.76	N/A	N/A	N/A	N/A	-219.64%	-96.00%	8/6/2025 (Estimated)
MGNX MacroGenics	-$9.06M	-$0.89	N/A	N/A	N/A	-69.07%	-89.42%	-38.57%	8/5/2025 (Estimated)
NKTX Nkarta	-$117.50M	-$1.51	N/A	N/A	N/A	N/A	-27.13%	-21.67%	8/12/2025 (Estimated)
VTL Vital Therapies	-$41.47M	N/A	0.00	∞	N/A	N/A	-235.33%	-182.35%	N/A

Latest VTL, EPRX, NKTX, and MGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A
5/13/2025	Q1 2025	MGNX MacroGenics	-$0.61	-$0.65	-$0.04	-$0.65	$9.59 million	$13.19 million
5/6/2025	Q1 2025	EPRX Eupraxia Pharmaceuticals	-$0.19	-$0.21	-$0.02	-$0.21	N/A	N/A
3/26/2025	Q4 2024	NKTX Nkarta	-$0.41	-$0.35	+$0.06	-$0.35	N/A	N/A
3/20/2025	Q4 2024	EPRX Eupraxia Pharmaceuticals	-$0.20	-$0.21	-$0.01	-$0.21	N/A	N/A
3/20/2025	Q4 2024	MGNX MacroGenics	-$0.23	-$0.25	-$0.02	-$0.25	$34.17 million	$49.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A
VTL Vital Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EPRX Eupraxia Pharmaceuticals	N/A	4.17	4.17
MGNX MacroGenics	N/A	3.75	3.69
NKTX Nkarta	N/A	12.91	12.91
VTL Vital Therapies	N/A	6.97	6.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EPRX Eupraxia Pharmaceuticals	N/A
MGNX MacroGenics	96.89%
NKTX Nkarta	80.54%
VTL Vital Therapies	15.52%

Insider Ownership

Company	Insider Ownership
EPRX Eupraxia Pharmaceuticals	N/A
MGNX MacroGenics	13.00%
NKTX Nkarta	8.40%
VTL Vital Therapies	33.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EPRX Eupraxia Pharmaceuticals	29	35.96 million	N/A	N/A
MGNX MacroGenics	430	63.09 million	55.67 million	Optionable
NKTX Nkarta	140	70.96 million	64.43 million	Optionable
VTL Vital Therapies	10	42.37 million	N/A	Not Optionable

VTL, EPRX, NKTX, and MGNX Headlines

Recent News About These Companies

18,000 vulnerable children could lose ‘vital’ therapy as adoption fund faces axe

March 31, 2025 | msn.com

Veterans Deserve Access To Life-Changing Psychedelics Therapy: A Vital Solution For PTSD And Healing

November 11, 2024 | benzinga.com

Respiratory Therapy program continues to thrive at Vermont State University

November 6, 2024 | vermontbiz.com

Respiratory Therapy program continues to thrive at Vermont State University

November 6, 2024 | vermontbiz.com

Lighthouse Center for Vital Living celebrates new building

October 30, 2024 | duluthnewstribune.com

Alternative Wellness Therapies in the Tahoe Basin

October 11, 2024 | tahoedailytribune.com

Addressing Trauma: A Vital Component in Behavioral Health

October 3, 2024 | ajmc.com

Vital Care Receives Strategic Investment From Berkshire Partners, Leonard Green & Partners, and Linden Capital Partners

August 1, 2024 | tmcnet.com

Veterans lobbied for psychedelic therapy, but it may not be enough to save MDMA drug application

July 26, 2024 | msn.com

Ending Therapy

May 24, 2024 | psychologytoday.com

Medication and Therapy

May 23, 2024 | psychologytoday.com

Vardhman Textiles Ltd.

May 22, 2024 | wsj.com

FDA’s Marks: Global Regulatory Convergence Vital to Cell & Gene Therapy Oversight

May 11, 2024 | biospace.com

Vital Spa celebrates a year on Bridge Street

April 28, 2024 | yahoo.com

Guest opinion: Psychedelics as a vital path to healing for veterans

April 28, 2024 | heraldextra.com

Don’t Forget About Vital Signs in Psychiatry Visits

March 12, 2024 | psychologytoday.com

What is therapeutic recreation? Champaign counselors train to include it in their sessions

March 8, 2024 | yahoo.com

Teen Therapy and Psychiatry Online: Hit or Miss?

March 3, 2024 | medpagetoday.com

Vital Ltd VTL

March 2, 2024 | morningstar.com

The Benefits of Teen Outpatient Programs for Behavioral Health

March 2, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTL, EPRX, NKTX, and MGNX Company Descriptions

Eupraxia Pharmaceuticals NASDAQ:EPRX

$3.86 -0.02 (-0.52%)

As of 06/13/2025 03:59 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

MacroGenics NASDAQ:MGNX

$1.52 -0.03 (-1.94%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.53 +0.01 (+0.66%)

As of 06/13/2025 07:54 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Nkarta NASDAQ:NKTX

$1.86 -0.05 (-2.62%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.88 +0.01 (+0.81%)

As of 06/13/2025 07:58 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Vital Therapies NASDAQ:VTL

Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time